Back to search
Cutaneous Leishmaniasis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cutaneous Leishmaniasis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cutaneous Leishmaniasis trials you may qualify forThis study will examine the natural history of Leishmanial infections and their treatments. It will provide an opportunity for NIAID staff to learn more about l…
Cutaneous leishmaniasis (CL) is a parasitic disease caused by more than 20 different species of the protozoan parasite Leishmania. CL usually begins with a papu…
Leishmaniasis is an infection caused by Leishmania parasites. In children, it can affect the skin or internal organs. Diagnosis may be delayed because the signs…
The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and com…
Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis. In an open…
randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alterna…
The purpose of this clinical trial is to measure efficacy, safety and pharmacokinetics (PK) of two LXE408 oral regimens and oral miltefosine tablets as active c…
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare acce…